SLU-PP-332
SLU-PP-332 Pan-ERR Agonist
SLU-PP-332 is a specialized synthetic small-molecule pan-agonist targeting estrogen-related receptors (ERRα, ERRβ, and ERRγ). First developed by researchers at Saint Louis University, the compound functions as a molecular exercise mimetic in preclinical investigations, driving transcriptional networks that normally respond to sustained physical training. In animal research models, administration of SLU-PP-332 has demonstrated marked increases in mitochondrial mass, improved oxidative phosphorylation, and enhanced endurance performance without prior exercise conditioning. It has also shown efficacy in promoting fatty acid oxidation and mitigating fat accumulation in diet-induced metabolic dysfunction models. This material is synthesized strictly for laboratory experimentation and scientific research purposes. It is not approved or intended for human or veterinary use, consumption, or therapeutic application.
Choose how to buy
Subscribe & save 5% on reshipsYour first order ships at the regular price. Every reship after that is 5% off. Pause, change the interval, or cancel anytime.
- Purity
- ≥99%
- Form
- Lyophilized powder
- CAS Number
- 2922115-40-8
- Molecular Formula
- C14H10F3NO3
- Molecular Weight
- 297.23 g/mol
- Available sizes
- 10mg
Mechanism of Action
SLU-PP-332 binds to and activates the nuclear receptor family of estrogen-related receptors, with high potency across ERRα, ERRβ, and ERRγ isoforms. This activation engages the PGC-1α transcriptional pathway, initiating downstream expression of genes crucial for mitochondrial biogenesis, electron transport chain function, and fatty acid oxidation. Through these nuclear pathways, SLU-PP-332 induces a phenotypic shift in skeletal muscle tissue toward highly oxidative Type I and IIa fibers, thereby accelerating lipid clearance and enhancing cellular bioenergetics in preclinical model systems.
Research Areas
- ●Mitochondrial biogenesis and respiration
- ●Exercise mimetic pathways
- ●Lipid metabolism and substrate utilization
- ●Skeletal muscle fiber-type remodeling
- ●Metabolic syndrome research
Selected References
- Billon C, et al. J Pharmacol Exp Ther. 2023;387(2):186-198.
- Schoepke E, et al. ACS Chem Biol. 2024;19(1):112-123.
- Elgendy B, et al. J Med Chem. 2022;65(14):9722-9739.
Related Products
